Pediatric Nephrology

, Volume 21, Issue 5, pp 729–732 | Cite as

Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists

  • Farida Daïkha-Dahmane
  • Evelyne Levy-Beff
  • Myriam Jugie
  • Richard Lenclen
Brief Report

Abstract

We report renal lesions observed in a foetus exposed throughout pregnancy to angiotensin II type I (AT 1) receptor antagonists. The mother suffered from essential hypertension and was treated with Cozaar (losartan 50 mg). Autopsy examination of the foetus revealed severe renal lesions, including tubular dysgenesis, hypertrophy of the endothelial and medial cells lining the arterial and arteriolar walls, hyperplasia of the juxtaglomerular apparatus and poorly developed vasa recta. Similar lesions have already been observed in foetuses of women treated with angiotensin-converting enzyme antagonists and also in foetuses and neonates of animals undergoing experimental blockade of the renin–angiotensin system. The purpose of this report is to describe structural lesions observed in the kidneys, and, particularly, vascular lesions. Our results suggest that the use of AT 1 receptor antagonists during pregnancy may have a severe deleterious effect on kidney development in the foetus.

Keywords

Fetal kidney AT 1 receptor antagonists Pregnancy 

References

  1. 1.
    Bermann MA, Walsh MF, Sowers JR (1997) Angiotensin II biochemistry and physiology: update on angiotensin II receptor blockers. Cardiovasc Drug Rev 15:75–100CrossRefGoogle Scholar
  2. 2.
    Saji H, Yamanaka M, Hagiwara A, Ljiri R (2001) Losartan and fetal toxic effects. Lancet 357:63CrossRefGoogle Scholar
  3. 3.
    Martinovic J, Benachi A, Laurent N, Daïkha-Dahmane F, Gubler MC (2001) Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 358:241–242PubMedCrossRefGoogle Scholar
  4. 4.
    Hinchliffe SA, Sargent PH, Howard CV, Chan YF, Hutton JL, Van Velzen D (1992) “Medullary ray glomerular counting” as a method of assessment of human nephrogenesis. Pathol Res Pract 188:775–782PubMedGoogle Scholar
  5. 5.
    Spence SG, Allen HL, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS (1995) Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 51:367–382PubMedCrossRefGoogle Scholar
  6. 6.
    Spence SG, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS (1995) Evaluation of the reproductive and developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 51:383–397PubMedCrossRefGoogle Scholar
  7. 7.
    Mehta N, Modi N (1989) ACE inhibitors in pregnancy. Lancet 8:96–97CrossRefGoogle Scholar
  8. 8.
    Knott PD, Thorpe SS, Lamont CAR (1989) Congenital renal dysgenesis possibly due to captopril. Lancet 25:451CrossRefGoogle Scholar
  9. 9.
    Cunniff C, Jones KL, Philipson J, Benirschke K, Short S, Wujek J (1990) Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 162:187–189PubMedGoogle Scholar
  10. 10.
    Shah MM, Sampogna V, Hiroyuki S, Bush KT, Nigam SK (2004) Branching morphogenesis and kidney disease. Development 131:1449–1462PubMedCrossRefGoogle Scholar
  11. 11.
    Bush KT, Sakurai H, Steer DL, Leonard MO, Sampogna RV, Meyer TN, Schwesinger C, Qiao J, Nigam SK (2004) TGF-β superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol 266:285–298PubMedCrossRefGoogle Scholar
  12. 12.
    Wolf G (2002) Angiotensin II and tubular development. Nephrol Dial Transplant 17:48–51PubMedCrossRefGoogle Scholar
  13. 13.
    Akil I, Inan S, Gurcu B, Nazikoglu A, Ozbilgin K, Muftuoglu S (2005) Histopathological and ultrastructural effects of losartan on embryonic rat kidney. Acta Histochem 107:291–300CrossRefGoogle Scholar
  14. 14.
    Friberg P, Sundelin B, Bohman SO, Bobik A, Nilsson H, Wickman A, Gustafsson H, Petersen J, Adams MA (1994) Renin–angiotensin system in neonatal rats: induction of a renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 45:485–492PubMedCrossRefGoogle Scholar
  15. 15.
    Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA (1995) Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 269:F110–F115PubMedGoogle Scholar
  16. 16.
    Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM (1995) Regulation of blood pressure by the type IA angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521–3525PubMedCrossRefGoogle Scholar
  17. 17.
    Friberg P, Guron G, Sundelin B, Wickman A, Adams MA (1996) Neonatal ACE inhibition in the pig causes irreversible abnormalities in the kidney. J Hypertens 14 [Suppl 1]:S54Google Scholar
  18. 18.
    Nilsson A, Adams M, Guron G, Sundelin B, Friberg P (1996) Reduced ability to excrete an acute volume load after neonatal ACE inhibition in the rat. J Am Soc Nephrol 7:1586Google Scholar
  19. 19.
    Nagata M, Tanimoto K, Fukamizu A, Kon Sugiyama F, Yagami K, Urakami K, Watanabe T (1996) Nephrogenesis and renovascular development in angiotensinogen-deficient mice. Lab Invest 75:745–753PubMedGoogle Scholar
  20. 20.
    Gomez RA (1998) Role of angiotensin in renal vascular development. Kidney Int 54 [Suppl]:S12–S16CrossRefGoogle Scholar
  21. 21.
    Sequeira Lopez MLS, Gomez RA (2004) The role of angiotensin II in kidney embryogenesis and kidney abnormalities. Curr Opin Nephrol Hypertens 13:117–122PubMedCrossRefGoogle Scholar
  22. 22.
    Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I (1998) Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 101:755–760PubMedCrossRefGoogle Scholar
  23. 23.
    Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, Ichiki T, Naftilan A, Fogo A, Inagami T, Hogan B, Ichikawa I (1995) Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 96:2947–2954PubMedCrossRefGoogle Scholar
  24. 24.
    Okubo S, Niimura F, Matsusaka T, Fogo A, Hogan B, Ichikawa I (1998) Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption. Kidney Int 53:617–625PubMedCrossRefGoogle Scholar
  25. 25.
    Freeburg PB, Abrahamson DR (2003) Hypoxia-inducible factors and kidney vascular development. J Am Soc Nephrol 14:2723–2730PubMedCrossRefGoogle Scholar
  26. 26.
    Karihaloo A, Karumanchi SA, Cantley WL, Venkatesha S, Cantley LG, Kale S (2005) Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion. Mol Cell Biol 25:7441–7448PubMedCrossRefGoogle Scholar
  27. 27.
    Kitamura S, Maeshima Y, Sugaya T, Sugiyama H, Yamasaki Y, Makino H (2003) Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells. Nephron Exp Nephrol 95:79–86CrossRefGoogle Scholar
  28. 28.
    Sanchez-Lopez E, Lopez AF, Esteban V, Yagüe S, Egido J, Ruiz-Ortega M, Alvarez-Arroyo MV (2005) Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1a induction and redox mechanisms in the kidney. Antioxid Redox Signal 7:1275–1284PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Farida Daïkha-Dahmane
    • 1
  • Evelyne Levy-Beff
    • 1
  • Myriam Jugie
    • 2
  • Richard Lenclen
    • 2
  1. 1.Service d’Anatomie Pathologique/Unité de FoetopathologieCentre Hospitalier de Poissy-Saint Germain en LayePoissy CedexFrance
  2. 2.Service de Réanimation NéonataleCentre Hospitalier de Poissy-Saint Germain en LayePoissy CedexFrance

Personalised recommendations